$GSK News

What Could GSK (LSE:GSK) Oncology Progress Mean For Investors?

Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial

Can Specialty Meds Offset GSK’s $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?

GSK (LSE:GSK) Secures Ex China Rights To KRAS EGFR Cancer Drug

How First In Class Hepatitis B Approval At GSK (LSE:GSK) Has Changed Its Investment Story

GSK (LSE:GSK) Stock May Trade At A Discount Despite Hibsago Approval

Why GSK Rose Even Though Profit Fell

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says

GSK Wins FDA Approval For Chronic Hepatitis B Drug

Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

FDA Approves First-Of-Its-Kind Chronic Hepatitis B Treatment; Approves Hibsago (Bepirovirsen) For Chronic Hepatitis B In Adults Without Cirrhosis

GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth

What Is GSK (LSE:GSK) Telling Investors With Its New Lung Cancer Data?

Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated

FDA Approves Immunotherapy That May Allow Certain Patients With Rectal Cancer To Avoid Chemotherapy, Radiation And Surgery

GSK lung cancer drug shows 61% response rate in early global trial

Global Restructuring And US Biologics Bet Could Be A Game Changer For GSK (LSE:GSK)

GSK (LSE:GSK) Following Its ADS Filing And The Case For Undervaluation